Elicera Therapeutics

The research grant from the Swedish Childhood Cancer Fund is awarded to Uppsala University, and the results generated in the project will contribute to the understanding of whether Elicera's cell therapy candidate ELC-401 could also be used in the future to treat brain tumors in children.

"We are very pleased that the Swedish Childhood Cancer Fund has given our co-founder Magnus Essand the confidence to continue developing his groundbreaking research at Uppsala University. The possibility of developing our cell therapy candidate ELC-401 in the future for the treatment of children with brain tumors is very interesting, and the size of the grant is a clear testament to the importance of Magnus Essand's contributions to cancer research and the potential of Elicera's development projects," says Jamal El-Mosleh, CEO of Elicera Therapeutics.